Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

RXR agonist IRX4204 induces ferroptosis in multiple myeloma via HMOX1/GPX4 axis and enhances lenalidomide efficacy

Jian Wu, Zhibo Yan, Kimberly Burcher et al. Nov 03, 2025 pp. 3950-3950 10.1182/blood-2025-3950

Abstract Background: Multiple myeloma (MM) remains incurable despite therapeutic advances, necessitating novel treatment strategies. Ferropto...

Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P

Zachary Epstein-Peterson, Nivetha Ganesan, Christina Poh et al. Nov 03, 2025 pp. 5410-5410 10.1182/blood-2025-5410

Abstract Background: DUSP22- and TP63-rearranged ALK- ALCL are distinct genetic subtypes with unique disease phenotypes and reported variabi...

Post-transplant cyclophosphamide significantly reduces early non-relapse mortality following allogeneic hematopoietic cell transplantation

Emily Wolf, Megan Melody, Athanasios Tsalatsanis et al. Nov 03, 2025 pp. 7820-7820 10.1182/blood-2025-7820

Abstract Introduction Survival following allogeneic hematopoietic cell transplantation (allo-HCT) has improved over the last several decades...

Heterogeneity of immune escape mechanisms in de novo Acute Myeloid Leukemia

Tiankai Yin, Michael Bern, Rachel Baits et al. Nov 03, 2025 pp. 5275-5275 10.1182/blood-2025-5275

Abstract Acute Myeloid Leukemia (AML) is a malignancy of hematopoietic stem/progenitor cells. Although immune checkpoint blockade has been e...

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

James Godfrey, Sravya Tumuluru, Alan Cooper et al. Nov 03, 2025 pp. 49-49 10.1182/blood-2025-49

Abstract Introduction: Genetic classification of diffuse large B-cell lymphoma (DLBCL) using LymphGen (LG) has provided critical insights in...

Developing SEMA4A-directed CAR t cells to overcome low BCMA antigen density in multiple myeloma

Francesca Albano, Francesco Di Meo, Annamaria Cesarano et al. Nov 03, 2025 pp. 6100-6100 10.1182/blood-2025-6100

Abstract Chimeric antigen receptor (CAR) T cell therapies targeting B cell maturation antigen (BCMA) have shown unprecedented activity in pa...

Real-world treatment patterns and clinical outcomes of therapies in primary immune thrombocytopenia

Sandhya Panch, Hongbo Yang, Su Zhang et al. Nov 03, 2025 pp. 6251-6251 10.1182/blood-2025-6251

Abstract Introduction: Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by low platelet counts, leading to a wide s...

Recurrent loss of chromosome y in multiple myeloma is linked to disease progression and altered tumor immune microenvironment

Luis Antonio Corchete Sánchez, Ema Klefti, Esther Rheinbay Nov 03, 2025 pp. 3942-3942 10.1182/blood-2025-3942

Abstract Introduction Sex-based disparities in multiple myeloma (MM) are well established, with men being more commonly affected than women,...

Safety and activity of gene therapy with AAV8 GBA1 (LY-M001)on type I adults gaucher disease

Yishan Ye, Xueping Luo, Jingwen Li et al. Nov 03, 2025 pp. 6098-6098 10.1182/blood-2025-6098

Abstract Background: Gaucher disease (GD) is a rare autosomal recessive disorder caused by GBA1 mutations, leading to deficient glucocerebro...

Real-world practices in the management of pediatric iliofemoral deep vein thrombosis, results of the elite-kids survey from the CHAT consortium

Maha Al-Ghafry, Ernest Amankwah, Brian Branchford et al. Nov 03, 2025 pp. 1355-1355 10.1182/blood-2025-1355

Abstract Background Deep vein thrombosis (DVT) of the extremities is the most common presentation of venous thromboembolism (VTE) in childre...

Torque teno virus in pediatric CAR-T recipients

Yasmina Mozo, Carolina del Pino, María Martín-Lunas et al. Nov 03, 2025 pp. 5937-5937 10.1182/blood-2025-5937

Abstract BACKGROUND Chimeric antigen receptor T-cell (CART) therapy has improved outcomes in relapsed/refractory (R/R) patients with B-acute...

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Jorge Labrador, David Martinez-Cuadron, Cristina Gil et al. Nov 03, 2025 pp. 875-875 10.1182/blood-2025-875

Abstract Introduction: Most patients with acute myeloid leukemia (AML) who receive palliative best supportive care (BSC) alone experience po...

A proteomics-driven machine learning tool for distinguishing ET from pre-PMF

Qing Wen, Sun Ting, Renchi Yang et al. Nov 03, 2025 pp. 1973-1973 10.1182/blood-2025-1973

Abstract Background: Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) are clinically overlapping but biologica...

Cellpolaris: A novel tool to quantify cell polarity reliably at scale in fixed and living cells

Soumen Bera, Jessica Nunes, Shalmali Pendse et al. Nov 03, 2025 pp. 1382-1382 10.1182/blood-2025-1382

Abstract Cell polarity, the asymmetric distribution of cellular constituents, is critical for many cellular functions, including cell migrat...

Real-world validation of ELN2024 and BEAT-AML2024 risk-stratification in patients with Acute Myeloid Leukemia unfit for intensive chemotherapy in a multicenter italian cohort.

Arianna Savi, Giovanni Fornari, Johanna Umurungi et al. Nov 03, 2025 pp. 1624-1624 10.1182/blood-2025-1624

Abstract Introduction: Acute myeloid leukemia (AML), a clonal neoplastic disease, mainly affects older adults, peaking at age 68, with two-t...

Survival after first relapse of pediatric B-ALL differs by insurance type: A real-world analysis from the recall-1 study

Katherine Lind, Abigale Berry, Yimei Li et al. Nov 03, 2025 pp. 6292-6292 10.1182/blood-2025-6292

Abstract BACKGROUND Children exposed to poverty during frontline therapy for B-lymphoblastic leukemia (B-ALL) experience inferior overall su...

Dissecting pirtobrutinib resistance in Mantle Cell Lymphoma through single-cell multi-omics

Fangfang Yan, Yang Liu, Heng-Huan Lee et al. Nov 03, 2025 pp. 1765-1765 10.1182/blood-2025-1765

Abstract Introduction Although the non-covalent BTK inhibitor Pirtobrutinib (PBN) has demonstrated clinical efficacy in treating relapsed an...

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Junia Vieira, Reyka Jayasinghe, Tarek Mouhieddine et al. Nov 03, 2025 pp. 3949-3949 10.1182/blood-2025-3949

Abstract Introduction: Extramedullary disease in multiple myeloma (EMD) is a clinically aggressive variant of multiple myeloma (MM), frequent...

Clinical implications and prevalence of benign ethnic neutropenia (BEN) in lymphoma patients of middle eastern ethnicity

Shruti Prem Sudha, Taif Najeebi, Nabil Abdelfattah et al. Nov 03, 2025 pp. 6184-6184 10.1182/blood-2025-6184

Abstract Background Benign ethnic neutropenia (BEN) commonly affects patients of African and Middle Eastern descent, and does not represent...

ARV-393, a PROTAC BCL6 degrader, combined with the CD20×CD3 bispecific glofitamab in a preclinical model of high-grade B-cell lymphoma (HGBCL)

Anna Van Acker, Emma Rousseau, Wendy Wu et al. Nov 03, 2025 pp. 1520-1520 10.1182/blood-2025-1520

Abstract Background: Despite significant progress made in the treatment of non-Hodgkin lymphoma (NHL) through advancements with immunochemot...

FLT3 ligand facilitates long-term ex vivo expansion of human hematopoietic stem cells by maintaining lymphoid reconstitution potential

Masashi Miyauchi, Allison Banuelos, Paul Mack et al. Nov 03, 2025 pp. 4931-4931 10.1182/blood-2025-4931

Abstract Hematopoietic stem cells (HSCs) are blood-forming stem cells that can reconstitute the entire blood system after transplantation, w...

Temporal trends in mortality due to Acute Myeloid Leukemia and sepsis in u.S. adults aged ≥25 years (1999–2023): A CDC wonder database analysis

Eshal Saghir, Maryam Saghir, Mahtab Zafar et al. Nov 03, 2025 pp. 6923-6923 10.1182/blood-2025-6923

Abstract Introduction: Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy affecting approximately 22,0...

Association of red blood cell transfusion and clinical outcomes in chimeric antigen receptor T-cell therapy: Insights from a six-year nationwide analysis

Adamsegd Gebremedhen, Abdu Mohammed, Samhitha Gundakaram et al. Nov 03, 2025 pp. 1365-1365 10.1182/blood-2025-1365

Abstract Background Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment paradigm for relapsed o...

Epitranscriptomic signatures define prognosis and therapeutic vulnerabilities in large B-cell lymphoma

Caroline Molinaro, Jeanne Loiseau, Andrea Romero et al. Nov 03, 2025 pp. 5312-5312 10.1182/blood-2025-5312

Abstract Introduction: Large B-Cell Lymphoma (LBCL) is an aggressive and the most common non-Hodgkin lymphoma, accounting for 30% of cases....

Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma

Max Köppel, Umair Munawar, Shilpa Kurian et al. Nov 03, 2025 pp. 2152-2152 10.1182/blood-2025-2152

Abstract Introduction: Although prior exposure to mutagenic agents like melphalan and lenalidomide is a known risk facto...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page